Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan

Japanese Journal of Infectious Diseases

Volumn 59, Issue 6, 2006, Pages 367-369

  Fukuda, Shinsaku ^a   Shimoyama, Tadashi ^a   Tanaka, Muneo ^a   Nakasato, Fumika ^a   Fukushi, Michio ^a   Munakata, Akihiro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DIGESTIVE TRACT ENDOSCOPY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DYSPEPSIA; FEMALE; HELICOBACTER INFECTION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; UNSPECIFIED SIDE EFFECT; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-INFECTIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TIME FACTORS;

EID: 33846017642     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Satoh, K. (2002): Indications for Helicobacter pylori eradication therapy and first-line therapy regimen in Japan: recommendation by the Japanese Society for Helicobacter Research. J. Gastroenterol., 37, Suppl. 13, 34-38.
2. Miwa, H., Misawa, H., Yamada, T., Nagahara, A., Ohtaka, K. and Sato, N. (2001): Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis. Dig. Dis. Sci., 46, 2445-2450.
3. Hoshiya, S., Watanabe, K., Tokunaga, K., Tanaka, A., Ninomiya, H., Shingaki, M., Itoh, T., Saito, S., Ishida, H. and Takahashi, S. (2000): Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J. Gastroenterol., 35, 10-14.
4. Hua, J.S., Bow, H., Zheng, P.Y. and Khay-Guan, Y. (2000): Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in Singapore. World J. Gastroenterol., 6, 119-121.
5. Yakoob, J., Fan, X., Hu, G., Liu, L. and Zhang, Z. (2001): Antibiotic susceptibility of Helicobacter pylori in the Chinese population. J. Gastroenterol. Hepatol., 16, 981-985.
6. Kato, M., Yamaoka, Y., Kim, J.J., Reddy, R., Asaka, M., Kashima, K., Osato, M.S., El-Zaatari, F.A., Graham, D.Y. and Kwon, D.H. (2000): Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob. Agents Chemother., 44, 2214-2216.
7. Murakami, K., Sato, R., Okimoto, T., Nasu, M., Fujioka, T., Kodama, M. and Kagawa, J. (2003): Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther., 17, 119-123.
8. Shimoyama, T., Fukuda, S., Mikami, T., Fukushi, M. and Munakata, A. (2004): Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J. Gastroenterol., 39, 927-930.
9. Nagahara, A., Miwa, H., Kawabe, M., Kurosawa, A., Asaoka, D., Hojo, M., Iijima, K., Terai, T., Ohkusa, T., Miyazaki, A. and Sato, N. (2004): Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen. J. Gastroenterol., 39, 1051-1055.
10. Adamek, R.J., Suerbaum, S., Pfaffenbach, B. and Opferkuch, W. (1998): Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence to treatment outcome. Am. J. Gastroenterol., 93, 386-389.
11. Poon, S.K., Chang, C.S., Su, J., Lai, C.H., Yang, C.C., Chen, G.H. and Wang, W.C. (2002): Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment. Pharmacol. Ther., 16, 291-296.
12. Perez-Aldana, L., Kato, M., Nakagawa, S., Kawarasaki, M., Nagasako, T., Mizushima, T., Oda, H., Kodaira, J., Shimizu, Y., Komatsu, Y., Zheng, R., Takeda, H., Sugiyama, T. and Asaka, M. (2002): The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter, 7, 306-309.
13. Versalovic, J., Shortridge, D., Kibler, K., Griffy, M.V., Beyer, J., Flamm, R.K., Tanaka, S.K., Graham, D.Y. and Go, M.F. (1996): Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pyloti. Antimicrob. Agents Chemother., 40, 477-480.
14. Graham, D.Y., Opekun, A.R., Belson, G., El-Zimaity, H.M. and Carlson, M.R. (2005): Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment. Pharmacol. Ther., 15, 165-168.
15. Graham, D.Y., Belson, G., Abudayyeh, S., Osato, M.S., Dore, M.P. and El-Zimaity, H.M. (2004): Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig. Liver Dis., 36, 384-387.
16. Beard, C.M., Noller, K.L., O'Fallon, W.M., Kurland, L.T. and Dahlin, D.C. (1988): Cancer after exposure to metronidazole. Mayo Clin. Proc., 63, 147-153.